Mode
Text Size
Log in / Sign up

Direct Transfer to Angiography Suite Shows No Benefit, Higher Hemorrhage Risk in Severe StrokeDoes rushing stroke patients straight to treatment improve their recovery?

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note: Direct transfer to angiography suite showed no functional benefit and higher hemorrhage risk in severe stroke trial stopped early for safety.

This multicenter randomized controlled trial at ten comprehensive stroke centers in France enrolled 115 adult patients (age ≤85 years) with acute severe neurological deficit highly suggestive of ischemic stroke from large vessel occlusion, admitted within 5 hours of symptom onset. Patients were assigned to either direct transfer to the angiography suite (DTAS, n=57) or the conventional pathway of imaging followed by transfer for endovascular treatment if eligible (n=58).

The primary outcome of functional independence (modified Rankin Scale score 0-2) at 90 days showed no significant difference between groups: 20 of 56 patients (36%) in the DTAS group versus 22 of 53 (42%) in the conventional group (adjusted odds ratio 0.73, 95% CI 0.32-1.69). All-cause mortality at 90 days also did not differ significantly (18% vs 11%; adjusted OR 1.65, 95% CI 0.52-5.55). A key safety finding was a significantly increased risk of symptomatic intracranial hemorrhage with DTAS (5 of 34 patients [15%] vs 0 of 42 [0%]; adjusted OR 11.0, 95% CI 1.28-1406).

Major limitations include the trial being stopped early for safety reasons and a small sample size that limits the precision of effect estimates for both the primary outcome and safety outcomes. Safety and tolerability details such as adverse events and discontinuations were not reported. The study was funded by the French Ministry of Health and Medtronic.

Given the lack of functional benefit, the concerning safety signal for hemorrhage, and the early trial termination, the direct transfer to angiography suite strategy cannot be recommended over conventional imaging-first pathways based on this evidence. Further clinical trials are required to firmly establish the safety and efficacy of this approach.

For someone having a major stroke, time is brain tissue. The standard process involves a CT scan to confirm the blockage before a patient is taken for a procedure to remove it. This trial asked a critical question: what if we skip that scan and take patients straight to the treatment room to save precious minutes?

The study involved 115 adults in France who showed clear signs of a severe stroke from a large blocked artery. They were randomly assigned to either go directly to the angiography suite for treatment or to follow the conventional path of imaging first. The main goal was to see how many people could live independently 90 days later.

The results were sobering. Rushing patients directly did not lead to more people regaining their independence. In fact, 36% in the direct-transfer group achieved this, compared to 42% in the conventional group—a difference that wasn't statistically significant. More concerning was the safety signal: patients taken directly had a higher rate of serious bleeding in the brain. Because of this safety worry, the trial was stopped early.

It's crucial to understand the limits of this finding. The study was small and ended prematurely, so we can't draw firm conclusions. The increased bleeding risk is a red flag that needs much more investigation. This doesn't mean the fast-track idea is dead, but it strongly suggests that skipping steps might come with unforeseen dangers that outweigh any potential time saved.

What this means for you:
Rushing stroke patients straight to treatment didn't improve recovery and raised safety concerns.

Study Details

Study typeRct
Sample sizen = 57
EvidenceLevel 2
Follow-up1020.0 mo
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Direct transfer to angiography suite (DTAS) for patients with suspected stroke primarily admitted to an endovascular-capable centre could accelerate in-hospital workflow and improve outcome. We aimed to assess the safety and efficacy of DTAS for patients with acute severe neurological deficit highly suggestive of ischaemic stroke due to a large vessel occlusion (ASND-LVO). METHODS: We did an open-label, multicentre, randomised controlled trial in ten comprehensive stroke centres in France. We enrolled adult patients (age ≤85 years) with ASND-LVO (unilateral motor deficit with a score ≥5 plus a cortical symptom with a score ≥1 based on the National Institues of Health Stroke Scale) admitted within 5 h of symptom onset. Patients were randomly assigned (1:1) with a web-based system to DTAS or conventional pathway (ie, imaging followed by transfer to the angiography suite for endovascular treatment if eligible). The primary outcome was functional independence defined as a modified Rankin Scale score 0 to 2 at 90 days in the intention-to-treat population-ie, all randomly assigned patients in their originally assigned treatment groups, irrespective of diagnosis, imaging findings, or treatments received. Symptomatic intracranial haemorrhage and all-cause mortality at 90 days were the main safety outcomes. This study was registered on ClinicalTrials.gov (NCT03969511). FINDINGS: Between July 9, 2020, and April 18, 2023, 115 patients were randomly assigned to the DTAS group (n=57) or the conventional group (n=58). An interim analysis was done on Sept 27, 2023. The trial steering committee permanently stopped the trial on Dec 1, 2023, for safety reasons after unmasking and analysis of the data. In the intention-to-treat analysis, the risk of symptomatic intracranial haemorrhage was increased in the DTAS group compared with the conventional group (five [15%] of 34 vs zero [0%] of 42; adjusted odds ratio [OR] 11·0 [95% CI 1·28-1406]). All-cause mortality did not differ significantly between groups (ten [18%] of 56 vs six [11%] of 53; adjusted OR 1·65 [95% CI 0·52-5·55]). Functional independence was reached in 20 [36%] of 56 participants in the DTAS group vs 22 [42%] of 53 in the conventional group (adjusted OR 0·73 [95% CI 0·32-1·69]). INTERPRETATION: DTAS for patients with ASND-LVO was associated with an increased risk of symptomatic intracranial haemorrhage without evidence of a beneficial effect on functional outcome at 90 days. However, because the trial was stopped early for safety reasons, the small sample size limits the precision of the effect estimates on the primary outcome and all secondary and safety outcomes. Therefore, further clinical trials are required to firmly conclude on the safety and efficacy of DTAS for patients with suspected acute ischaemic stroke due to a large vessel occlusion. FUNDING: French Ministry of Health and Medtronic.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.